About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

Kcentra Approved to Stop Severe Bleeding in Heart Patients

Can be given faster than plasma
TUESDAY, April 30, 2013 (HealthDay News) -- Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and similar products.
Blood plasma is the only other product approved for this use, the FDA said in a news release, but plasma requires blood typing and may require thawing. This means Kcentra usually can be administered more quickly than plasma to stop major bleeding.
Warfarin and similar anticoagulants are typically prescribed in cases of atrial fibrillation (irregular heartbeat) and for people with an artificial heart valve, the FDA said.
Kcentra will carry a boxed label warning that it may increase users' risk of blood clots. Made from the pooled plasma of screened donors, it's processed to minimize recipients' risk of acquiring viruses and other germs, the agency said.
In a study of 216 people who had been receiving anticoagulation therapy and who developed major bleeding, Kcentra was found to be as effective as plasma in treating the problem, the FDA said.
The drug is produced by the German company CSL Behring.
More information
To learn more about this approval, visit the FDA (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm350026.htm ).
Health Headlines
Halloween at the ER Is No TreatView in a lightbox
Almost 1 in 5 Americans Plagued by Constant Pain, Survey SuggestsView in a lightbox
Child's Appendix More Likely to Rupture in Regions Short of SurgeonsView in a lightbox
Generic Drugs May Help Breast Cancer Patients Stick to TherapyView in a lightbox
Health Highlights: Oct. 31, 2014View in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices | Talks Your Health